Hengrui Pharmaceutical announced that the company will license the GLP-1 product portfolio with independent intellectual property rights to Hercules of the United States for a fee, and Hercules of the United States will obtain the exclusive right to develop, produce and commercialize the GLP-1 product portfolio on a global scale other than Greater China. As part of the consideration for the foreign licensing transaction, Hengrui will acquire 19.9% of the shares in Hercules of the United States and will obtain licensing fees for the GLP-1 product portfolio from Hercules of the United States.
恒瑞医药：将取得美国Hercules公司19.9%的股权
Hengrui Pharmaceutical: Will acquire 19.9% of the shares of Hercules in the United States
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.